OSE-127 (Effi-7), in preclinical stage, developed for autoimmune diseases and transplantation

OSE-127 (Effi-7) is a humanized monoclonal antibody targeting the CD 127 receptor — the alpha chain of the Interleukin 7 receptor (IL-7R). Effi-7 possesses a novel mechanism of action: by simultaneously blocking the Interleukin 7 receptor and the formation of new alpha-gamma complex, it induces a strong antagonist effect, resulting in a better control of T-cells.

The Interleukin 7 plays a major role in the pathophysiology of autoimmune diseases such as ulcerative colitis, a pathology developed as part of the consortium EFFIMab (see below).

Proof of concept confirmed in relevant in vitro and in vivo models

OSE-127 (Effi-7) has shown efficacy in preclinical models of T-cell-mediated inflammation, with an immediate and long-lasting effect, conferring the product a novel mechanism of action.

The strategy of blocking IL-7R, which is different from conventional or new anti-inflammatory drugs used in the clinic, demonstrated its efficacy in several preclinical models, restoring the impaired immune balance in inflammatory bowel diseases (references), type 1 diabetes, multiple sclerosis and rheumatoid arthritis. Read more >

It also enabled the promotion of immune tolerance in allotransplantation, as demonstrated by Jean-Paul Soulillou’s team, in collaboration with Efffimune in 2014 (reference). Read more >

License option agreement with Servier to develop and commercialize OSE-127 (Effi-7)

On December 28, 2016, OSE Immunotherapeutics has granted Servier, an independent international pharmaceutical company, a license option on the exclusive worldwide rights for the development and commercialization of its product OSE-127 (Effi-7). These steps will enable the development of the product up to the completion of a phase 2 clinical trial planned in ulcerative colitis, an autoimmune bowel disease (Read the press release).

Attaining preclinical and clinical proofs of concept for OSE-127 (Effi-7) are the main goals of EFFIMab, a multidisciplinary program led by OSE Immunotherapeutics researchers along with several academic and private partners. This €20 million program is funded by the French public investment bank (Bpifrance) under the Industrial-Strategic-Innovation (ISI) program, which will finance a significant portion of the expenses incurred.

Réferences

  1. Schluns, K. S. & Lefrançois, L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 3, 269–279 (2003).
  2. Dooms, H. Interleukin-7: Fuel for the autoimmune attack. J. Autoimmun. 45, 40–48 (2013).
  3. Liu, W. et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203, 1701–1711 (2006).
  4. Michel, L. et al. Patients with relapsing-remitting multiple sclerosis have normal Treg function when cells expressing IL-7 receptor alpha-chain are excluded from the analysis. J. Clin. Invest. 118, 3411–3419 (2008).
  5. Seddiki, N. et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203, 1693–1700 (2006).
  6. Powell, N. et al. The transcription factor T-bet regulates intestinal inflammation mediated by interleukin-7 receptor+ innate lymphoid cells. Immunity 37, 674–684 (2012).
  7. Shinohara, T. et al. Upregulated IL-7 receptor α expression on colitogenic memory CD4+ T cells may participate in the development and persistence of chronic colitis. J. Immunol. 186, 2623–2632 (2011).
  8. Totsuka, T. et al. IL-7 Is essential for the development and the persistence of chronic colitis. J. Immunol. 178, 4737–4748 (2007).
  9. Watanabe, M. et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J. Exp. Med. 187, 389–402 (1998).
  10. 10. Watanabe, M. et al. The serum factor from patients with ulcerative colitis that induces T cell proliferation in the mouse thymus is interleukin-7. J. Clin. Immunol. 17, 282–292 (1997).
  11. 11. Watanabe, M. et al. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J. Clin. Invest. 95, 2945–2953 (1995).
  12. 12. Willis, C. R. et al. Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis. J Inflamm (Lond) 9, 39 (2012).
  13. Yamazaki, M. et al. Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J. Immunol. 171, 1556–1563 (2003).
  14. Lee, L.-F. et al. Anti-IL-7 receptor-α reverses established type 1 diabetes in nonobese diabetic mice by modulating effector T-cell function. Proceedings of the National Academy of Sciences of the United States of America (2012). doi:10.1073/pnas.1203795109
  15. Penaranda, C. et al. IL-7 receptor blockade reverses autoimmune diabetes by promoting inhibition of effector/memory T cells. Proceedings of the National Academy of Sciences of the United States of America (2012). doi:10.1073/pnas.1203692109
  16. Lee, L.-F. et al. IL-7 promotes T(H)1 development and serum IL-7 predicts clinical response to interferon-β in multiple sclerosis. Sci Transl Med 3, 93ra68 (2011).
  17. Liu, X. et al. Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease. Nat. Med. 16, 191–197 (2010).
  18. Hartgring, S. A. Y. et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum. 62, 2716–2725 (2010).
  19. Hartgring, S. A. Y. et al. Elevated expression of interleukin-7 receptor in inflamed joints mediates interleukin-7-induced immune activation in rheumatoid arthritis. Arthritis Rheum. 60, 2595–2605 (2009).
  20. Hartgring, S. A. Y., Bijlsma, J. W. J., Lafeber, F. P. J. G. & van Roon, J. A. G. Interleukin-7 induced immunopathology in arthritis. Ann. Rheum. Dis. 65 Suppl 3, iii69–74 (2006).
  21. Van Roon, J. A. G. et al. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 664–669 (2007).
  22. Mai, H.-L. et al. IL-7 receptor blockade following T cell depletion promotes long-term allograft survival. J. Clin. Invest. 124, 1723–1733 (2014).